Sanofi ( SNY ) recently
announced that it has started constructing a new manufacturing
facility in the Saigon High Tech Park - Ho Chi Minh City, Vietnam.
Sanofi plans to invest approximately $75 million on this new plant.
The new plant is expected to be fully operational by the end of
The manufacturing facility is expected to produce pharmaceuticals
and consumer healthcare products with an initial capacity of 90
million units per year, which is expandable up to 150 million
We believe that the manufacturing facility will help Sanofi to
meet the demand in Vietnam and Association of South East Asian
Nations (ASEAN) markets.
The signing of the deal comes close on the heals of Sanofi's
collaboration with a French biopharmaceutical company, Transgene,
for the production of immunotherapy products and creating of an
industrial platform for the same. The platform will include
Sanofi and Transgene will invest €10 million in the platform,
which will be located at the Genzyme Polyclonals site at Lyon,
Gerland. The platform will be solely owned by Sanofi.
Construction, qualification and validation of the manufacturing
facility are expected to commence in the third quarter of 2013.
Sanofi expects the first batch of commercial grade drugs to be
available in 2015.ABBOTT LABS (ABT): Free Stock Analysis ReportLILLY ELI & CO (LLY): Free Stock Analysis
ReportNOVO-NORDISK AS (NVO): Free Stock Analysis
ReportSANOFI-AVENTIS (SNY): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment
We note that Sanofi is looking to combat the threat of
genericization hanging over many of its drugs by signing
deals/making acquisitions. The company's focus on the high
potential emerging markets is also impressive.
Sanofi carries a Zacks Rank #3 (Hold) in the short run. However,
large cap pharma stocks such as Novo Nordisk ( NVO ), Eli
Lilly and Company ( LLY ) and
Abbott Laboratories ( ABT ) currently look
more attractive. All three stocks carry a Zacks Rank #2 (Buy).